A Study to Learn About the Study Medicine (Called Maplirpacept (PF-07901801)) in Japanese With Hematologic Malignancies

Inclusion Criteria:

* Relapsed or refractory lymphoma (Hodgkin's or non-Hodgkin's) or multiple myeloma
* Disease must have progressed with standard anticancer therapies
* measurable disease
* Capable of giving signed informed consent
* Eastern cooperative oncology group performance status 0 or 1
* Adequate organ functions

Exclusion Criteria:

* Known, current central nervous system or interstitial lung disease involvement
* History of hemolytic anemia or positive direct antiglobulin test or active bleeding disorder
* Chronic use of systemic corticosteroids of more than 20 mg/day of prednisone or equivalent
* Significant cardiovascular disease
* Other significant medical condition unrelated to the primary malignancy
* Radiation therapy within 14 days of study treatment administration
* Hematopoietic stem cell transplant within 90 days before the planned start of study treatment
* Antiplatelet/anticoagulant agents within 14 days before planned start of study treatment
* Patients sustaining major surgery at least 4 weeks prior to study enrollment
* Use of any investigational agent or any anticancer drug within 14 days before planned start of study treatment
* Prior anti-CD47 and anti-Signal Regulatory Protein alpha therapy
* Active, uncontrolled bacterial, fungal, or viral infection
* Investigator site staff directly involved in the conduct of the study and their family members